Quality Control for IG /TR Marker Identification and MRD Analysis.
Acute lymphoblastic leukemia
Minimal residual disease
Next-generation sequencing
PCR
Quality control
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
1
6
2022
Statut:
ppublish
Résumé
Selection of the proper target is crucial for clinically relevant monitoring of minimal residual disease (MRD) in patients with acute lymphoblastic leukemia using the quantitation of clonal-specific immunoreceptor (immunoglobulin/T cell receptor) gene rearrangements. Consequently, correct interpretation of the results of the entire analysis is of utmost importance. Here we present an overview of the quality control measures that need to be implemented into the process of marker identification, selection, and subsequent quantitation of the MRD level.
Identifiants
pubmed: 35622322
doi: 10.1007/978-1-0716-2115-8_6
pmc: PMC9761552
doi:
Substances chimiques
Biomarkers
0
Immunoglobulins
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-99Informations de copyright
© 2022. The Author(s).
Références
Leukemia. 2019 Sep;33(9):2254-2265
pubmed: 31227779
Leukemia. 1999 Jan;13(1):110-8
pubmed: 10049045
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Leukemia. 2003 Jun;17(6):1013-34
pubmed: 12764363
BMC Genomics. 2014 May 28;15:409
pubmed: 24885090
Bioinformatics. 2017 Feb 1;33(3):435-437
pubmed: 28172348
Bone Marrow Transplant. 2017 Jul;52(7):962-968
pubmed: 28244980
Leukemia. 2008 Mar;22(3):641-4
pubmed: 17851557
Bone Marrow Transplant. 2008 Aug;42(3):187-96
pubmed: 18490915
Leukemia. 2019 Sep;33(9):2241-2253
pubmed: 31243313
Blood. 1999 Jun 15;93(12):4079-85
pubmed: 10361104
Leukemia. 2007 Apr;21(4):604-11
pubmed: 17287850